Trade MerckCo USA ^MRK

Pharmaceutical Stocks To Watch Now - October 3rd - Zolmax

Merck & Co., Inc. $MRK Stake Trimmed by CX Institutional

Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $180.00 - Zolmax

MSD's Phase IIb study of tulisokibart achieves primary endpoint

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Promising Pharmaceutical Stocks Worth Watching - September 30th

Andrew Moffs' Market Outlook: Real Estate Stocks - BNN Bloomberg

U.S. import ban on select Canadian goods takes effect - BNN Bloomberg

Recent Investment Analysts' Ratings Changes for Merck & Co., Inc. (MRK) - Daily Political

Merck (MRK) Withdrew a Cancer Filing. Is the Drug's Promise Still Intact?

Best Pharmaceutical Stocks To Follow Now - September 26th - Daily Political

Merck & Co (MRK) Has Billions in Revenue to Defend. Can its Pipeline Do the Job?

Promising Pharmaceutical Stocks To Research - September 28th - Zolmax

Kodiak soars on double phase III win in wet AMD

Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics - Update | Morningstar

Merck (MRK) Secures Exclusive Rights to Cancer Drug in $2.13B SciBrunch Agreement

Merck, Daiichi end plans to seek speedy approval of lung cancer ADC

Merck Signs $2.13 Bln License Deal With SciBrunch Therapeutics For KRAS G12D Inhibitor

Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics | Morningstar

CAPVAXIVE® Included in Ontario's Publicly Funded Adult Pneumococcal Immunization Program | INN

Daiichi Sankyo, MSD withdraw cancer drug application

Daiichi, Merck withdraw BLA for B7-H3 ADC in small-cell lung cancer | BioWorld

Merck licenses SPR-2015 from China's Scibrunch in $2B+ deal | BioWorld

Promising Pharmaceutical Stocks To Consider - September 27th - Zolmax

Merck (MRK) Withdraws I-DXd Biologics License Application for ES

Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment | Morningstar

J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)

Merck reveals study success, and possible safety worries, for eye drug hopeful

Merck sees pivotal victory for $3B eye disease prospect

Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK

Envestnet Asset Management Inc. Has $513.60 Million Stock Holdings in Merck & Co., Inc. $MRK

DME red flag in Merck Brunello phase III? Surrozen finishes rich | BioWorld

QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK

Healthcare Stocks To Add to Your Watchlist - September 23rd - Stock Observer

Merck & Co., Inc. (NYSE:MRK) Upgraded at Wall Street Zen - Zolmax

State Street Corp Has $15.57 Billion Position in Merck & Co., Inc. $MRK

Bladder Cancer Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight | ABNewswire

Merck's KEYTRUDA QLEX Approved In Japan For Subcutaneous Use

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)

Merck & Co., Inc. (NYSE:MRK) Upgraded by Wall Street Zen to Buy Rating - Stock Observer

Merck & Co., Inc. (NYSE:MRK) Stock Rating Upgraded by Wall Street Zen

Promising Healthcare Stocks To Consider - September 19th - Markets Daily

Merck (MRK) Stock: Surge as HIV Health Campaign Launches at USCHA 2026

Nykredit A S Invests $92.32 Million in Merck & Co., Inc. $MRK

Top Pharmaceutical Stocks Worth Watching - September 17th - Markets Daily

Merck & Co. (MRK) is Building a Stronger Future Beyond Its Keytruda Franchise

Oncology Tie-Up and Blockchain Pilot Might Change The Case For Investing In Merck (MRK)

Merck & Co Inc's Dividend Analysis

RBC Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

RBC Capital Sticks to Their Buy Rating for Roche Holding AG (RHHVF)

RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)

GlaxoSmithKline (GSK) Gets a Hold from RBC Capital

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

RBC Capital Keeps Their Hold Rating on Novartis AG (NOVN)

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Congresswoman Bets on Elon Musk, Warren Buffett: Here's the Latest Stock Transactions

Top Pharmaceutical Stocks To Research - September 14th - Daily Political

Wall Street Zen Downgrades Merck & Co., Inc. (NYSE:MRK) to Hold - Stock Observer

Merck & Co., Inc. (MRK) to Issue Quarterly Dividend of $0.85 on October 7th - Zolmax

Pharmaceutical Stocks To Keep An Eye On - September 13th - Daily Political

Pharmaceutical Stocks To Follow Today - September 12th - Stock Observer

Merck & Co., Inc. (NYSE:MRK) Lowered to Hold Rating by Wall Street Zen

Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $161.00 - Daily Political

7,741 Shares in Merck & Co., Inc. $MRK Bought by Talon Private Wealth LLC

Smith Chas P & Associates PA Cpas Has $46.21 Million Stake in Merck & Co., Inc. $MRK - Daily Political

MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE

The Manufacturers Life Insurance Company Has $266.40 Million Position in Merck & Co., Inc. $MRK

Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of "Moderate Buy" by Brokerages

IPG Investment Advisors LLC Lowers Position in Merck & Co., Inc. $MRK

Merck & Co., Inc. $MRK Shares Sold by Corient Private Wealth LP

Rep. Maria Elvira Salazar Buys Merck & Co., Inc. (NYSE:MRK) Stock

RBC Capital Sticks to Its Buy Rating for Johnson & Johnson (JNJ)

RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)

Merck & Co., Inc. (NYSE:MRK) Trading Down 1.9% - Should You Sell?

MSD opens 2.5 lakh sqft technology centre in Hyderabad

MRK Maintained by HSBC -- Price Target Raised to $172

HSBC Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price - Stock Observer

Integrated Wealth Concepts LLC Acquires 13,850 Shares of Merck & Co., Inc. $MRK

Archford Capital Strategies LLC Has $3.52 Million Position in Merck & Co., Inc. $MRK

MRK Maintains Outperform Rating by Leerink Partners -- Price Tar

Merck & Co., Inc. (NYSE:MRK) Given New $161.00 Price Target at Leerink Partners

The Zacks Analyst Blog Highlights Oracle, Merck, Union Pacific, CVD Equipment and Koil Energy Solutions

Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $161.00 - Stock Observer

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma...

NewEdge Advisors LLC Purchases 41,950 Shares of Merck & Co., Inc. $MRK

Merck & Co., Inc. $MRK Shares Purchased by Ameritas Advisory Services LLC

Bank of America Securities Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

NewEdge Advisors LLC Acquires 41,950 Shares of Merck & Co., Inc. $MRK - Daily Political

RBC Capital downgrades Novartis AG (NOVN) to a Hold

RBC Capital downgrades GlaxoSmithKline (GSK) to a Hold

RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

Top Stock Reports for Oracle, Merck & Union Pacific

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Week ahead: Apple leads big tech earnings, UK Budget and Nonfarm Payrolls

Week ahead: Eurozone inflation, Fed meeting, Apple earnings

Week ahead: Wall Street’s Magnificent Seven earnings are up

Week ahead: Fed, BoE to hold; Apple leads big tech earnings

Moderna share price jumps as Oppenheimer upgrades stock

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk